Insider · CIK 0001816720
Scott Akamine
Files at CERE (Cerevel Therapeutics Holdings, Inc.), KLRA (Kailera Therapeutics, Inc.). First filing Dec 7, 2023, latest Dec 21, 2023.
In brief
Scott Akamine files SEC Form 4 as officer at CERE (Cerevel Therapeutics Holdings, Inc.), and also at KLRA (Kailera Therapeutics, Inc.). Since Dec 7, 2023, Scott Akamine has reported 0 open-market buys worth $0 and 2 open-market sells worth $969k, the latest filed on Dec 21, 2023.
A track record needs three past buys with six months of prices behind them; Scott Akamine has 0, so none is measured yet.
The newest scored trade: sold $293k of CERE on Dec 20, 2023, filed Dec 21, 2023, scored 39 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Cerevel Therapeutics Holdings, Inc. | $293k 7,072 shares | -49% | - | |
| 28Weak | Cerevel Therapeutics Holdings, Inc. | $676k 17,500 shares | -218% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 7, 2023 | CEREVEL THERAPEUTICS HOLDINGS, INC. | 10,000 0.01% of outstanding | $414k | Dec 7, 2023 | $263k |
| Dec 5, 2023 | CEREVEL THERAPEUTICS HOLDINGS, INC. | 7,500 0.00% of outstanding | $263k | Dec 5, 2023 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Apr 20, 2026 |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Apr 20, 2026 |
| Dec 19, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Common Stock | +13,796 | - | - | 14,309 | Dec 21, 2023 |
| Dec 20, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | SOpen-market sale Common Stock | -7,072 | $41.42 | $293k | 7,237 | Dec 21, 2023 |
| Dec 19, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Restricted Stock Unitsderivative | -13,796 | $0.00 | $0 | 0 | Dec 21, 2023 |
| Dec 5, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Common Stock10b5-1 | +7,500 | $13.17 | $99k | 8,013 | Dec 7, 2023 |
| Dec 5, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -7,500 | $35.00 | $263k | 513 | Dec 7, 2023 |
| Dec 7, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Common Stock10b5-1 | +10,000 | $13.17 | $132k | 10,513 | Dec 7, 2023 |
| Dec 7, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $41.37 | $414k | 513 | Dec 7, 2023 |
| Dec 5, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 264,262 | Dec 7, 2023 |
| Dec 7, 2023 | CERE Cerevel Therapeutics Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 254,262 | Dec 7, 2023 |
Questions about Scott Akamine
Answered from the filings on this page, as of the latest one.
Is Scott Akamine buying or selling?
Not in the last 12 months. Scott Akamine's latest open-market trade on SEC Form 4 was sold $293k of CERE on Dec 20, 2023.
How did Scott Akamine's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Scott Akamine has 0.
Where does Scott Akamine file Form 4?
Scott Akamine has filed Form 4 at CERE (Cerevel Therapeutics Holdings, Inc.) as Chief Legal Officer; KLRA (Kailera Therapeutics, Inc.) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.